No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Very Low
Coadministration with emtricitabine/tenofovir-DF has not been studied. Ribavirin is partly metabolized (non CYP mediated) and partly excreted in the urine and an interaction with emtricitabine is not expected. Coadministration of tenofovir-DF (300 mg once daily) and ribavirin (600 mg single dose) had no clinically significant effect on ribavirin pharmacokinetics (AUC increased 26% and Cmax decreased 5%). Tenofovir pharmacokinetics were similar to those observed in previous studies.